Small molecule nucleic acid drug for intervening in cancer-specific LINC00942 and application of small molecule nucleic acid drug in targeted therapy of liver cancer
By designing siRNA specifically targeting LINC00942 to coupling with GalNAc, the delivery problem of siRNA in liver cancer cells is solved, and precise treatment of liver cancer cells is achieved, inhibiting liver cancer growth and reducing side effects.
CN120284998AActive Publication Date: 2025-07-11FUDAN UNIV SHANGHAI CANCER CENT
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202510213517.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-26
- Publication Date
- 2025-07-11
- Estimated Expiration
- 2045-02-26
AI Technical Summary
Technical Problem
The prior art is difficult to effectively deliver siRNA to liver cancer cells, resulting in poor therapeutic effects on liver cancer and problems such as off-target effects, immunogenicity and drug resistance.
Method used
The siRNA sequence specifically targeting LINC00942 was designed and coupled to the GalNAc ligand, and GalNAc was used to bind to the ASGPR receptor on the surface of hepatocytes to achieve accurate delivery of siRNA.
Benefits of technology
The specific silencing of LINC00942 was achieved, which significantly inhibited the growth of liver cancer cells and reduced side effects, providing a new strategy for targeted liver cancer treatment.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention provides a small molecule nucleic acid drug for intervening in cancer specific LINC00942 and application of the small molecule nucleic acid drug in targeted therapy of liver cancer, and discovers a non-coding RNA LINC00942 with high expression in liver cancer and capable of promoting cancer length, and the non-coding RNA LINC00942 is used as a potential target for treating liver cancer. According to the present invention, the siRNA sequence specifically targeting LINC00942 is designed, and the siRNA sequence is coupled with the GalNAc ligand; the GalNAc can be combined with an ASGPR receptor which is specifically expressed on the surface of the hepatocyte, so that the siRNA conjugate is accurately delivered into the hepatocyte. According to the method, the problem of siRNA delivery is effectively solved, and specific silencing of LINC00942 is realized, so that the purpose of inhibiting growth of liver cancer cells is achieved. Besides, the invention provides a novel liver cancer treatment method, and the effect of targeted treatment of liver cancer is achieved by specifically silencing LINC00942 with high expression of liver cancer by using a GalNAc mediated siRNA delivery system.
Need to check novelty before this filing date? Find Prior Art